-
Product Insights
Juvenile Macular Degeneration (Stargardt Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Juvenile Macular Degeneration (Stargardt Disease) - Drugs In Development, 2023’, provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Sector Analysis
Juvenile Macular Degeneration (JMD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Juvenile Macular Degeneration (JMD) Marketed and Pipeline Drugs Overview JMD, also called juvenile macular dystrophy, is a group of inherited eye disorders that affects children and young adults, disturbing their central vision. JMD is classified into three major types: Stargardt disease, X-linked retinoschisis (juvenile retinoschisis), and Best vitelliform macular dystrophy (Best’s disease). In the 16MM (Australia, Brazil, China, Canada, France, Germany, India, Italy, Japan, Mexico, Russia, South Africa, South Korea, Spain, UK, and the US), epidemiologists estimate there were around...